THURSDAY, OCTOBER 20

6:00 p.m.–7:00 p.m.	**Opening Keynote Address** Salons EF
6:00 p.m.–7:00 p.m.	Title to be announced Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA
7:00 p.m.–8:30 p.m.	**Opening Reception** Back Bay

FRIDAY, OCTOBER 21

7:30 a.m.–8:30 a.m.	**Breakfast and Mentoring Roundtables** Back Bay
8:30 a.m.–10:30 a.m.	**Session 1: Controlling Inflammation in the Tumor Microenvironment** Salons EF
	Session Chairperson: Laurie H. Glimcher, Dana-Farber Cancer Institute, Boston, MA
8:30 a.m.–9:00 a.m.	Functional role of endogenous retroviruses in cancer immunity Reiner Strick, University-Clinic Erlangen, Erlangen, Germany
9:00 a.m.–9:30 a.m.	Anti-tumor T cells: You are what you eat Susan M. Kaech, Yale University School of Medicine, New Haven, CT
9:30 a.m.–10:00 a.m.	Stressed out: A novel approach to cancer immunotherapy Laurie H. Glimcher
10:00 a.m.–10:15 a.m.	Blocking Colony Stimulating Factor 1 Receptor (CSF-1R) and Tropomyosin Receptor Kinase (Trk) improves antitumor efficacy of immunotherapy* Stephen Mok, The University of Texas MD Anderson Cancer Center, Houston, TX
10:15 a.m.–10:30 a.m.	Antigen delivery targeting tumor-infiltrating macrophages leads to eradication of tumor highly resistant to immune checkpoint inhibitors* Daisuke Muraoka, University of Shizuoka, Shizuoka, Japan
10:30 a.m.–11:00 a.m.	**Break** Salons EF Foyer

*Short talk from proffered abstract

11:00 a.m.-1:00 p.m. **Session 2: Key Immuno-Modulatory Cell Subsets**
Salons EF

Session Chairperson: Miriam Merad, Mount Sinai Icahn School of Medicine, New York, NY

11:00 a.m.-11:30 a.m. Innate lymphoid cells regulate the functional properties of tumor infiltrating T cells
Pamela S. Ohashi, Princess Margaret Cancer Centre, Toronto, ON, Canada

11:30 a.m.-12:00 p.m. Role of TCR specificity in regulatory T cell selection
Chyi-Song Hsieh, Washington University, St. Louis, MO

12:00 p.m.-12:30 p.m. Myeloid cell contribution to tumor inflammation
Miriam Merad

12:30 p.m.-12:45 p.m. Prophylactic nodal irradiation abrogates the synergy of tumor radiotherapy and immune checkpoint blockade*
Ariel E. Marciscano, Johns Hopkins University School of Medicine, Baltimore, MD

12:45 p.m.-1:00 p.m. Targeting regulatory T cells via LAP promotes anti-tumor immunity by decreasing CD103+CD8+ T cells*
Galina Gabriely, Harvard Medical School, Boston, MA

1:00 p.m.-3:00 p.m. **Lunch on own/Free time**

3:00 p.m.-5:15 p.m. **Session 3: Immunomodulation**
Salons EF

Session Chairperson: Arlene H. Sharpe, Harvard Medical School, Boston, MA

3:00 p.m.-3:30 p.m. Immune checkpoint blockade in cancer therapies: New insights, opportunities, and prospects for cures
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX

3:30 p.m.-4:00 p.m. Title to be announced
Arlene H. Sharpe

4:00 p.m.-4:30 p.m. The interferon receptor pathway's role in response and resistance to PD-1 blockade
Antoni Ribas, UCLA Medical Center, Los Angeles, CA

4:30 p.m.-4:45 p.m. Combinatorial proteomic analysis of the receptor programmed cell death-1 uncovers new checkpoint modulators*
Michael Peled, New York University School of Medicine, New York, NY

4:45 p.m.-5:00 p.m. A LAG-3/PD-L1 bispecific antibody inhibits tumour growth in two syngeneic colon carcinoma models*
Katy Everett, F-star Biotechnology Ltd., Cambridge, United Kingdom
(Not eligible for CME)

5:00 p.m.-5:15 p.m. Use of a novel mouse model to investigate immune related adverse events arising from immunotherapies*
Stephen J. Blake, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

5:15 p.m.-7:45 p.m. **Poster Session A and Reception**
Back Bay

*Short talk from proffered abstract

SATURDAY, OCTOBER 22

7:30 a.m.–8:30 a.m.	**Breakfast and Mentoring Roundtables** Back Bay
8:30 a.m.–10:30 a.m.	**Session 4: New CARs** Salons EF
	Session Chairperson: Marcela V. Maus, Massachusetts General Hospital, Charlestown, MA
8:30 a.m.–9:00 a.m.	Adapting CARs for solid tumors Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY
9:00 a.m.–9:30 a.m.	Combating antigen escape with CD19/CD20 bispecific CAR-T cell therapy Yvonne Y. Chen, Univeristy of California, Los Angeles, CA
9:30 a.m.–10:00 a.m.	CAR-T cells for solid tumors: What have we learned so far? Marcela V. Maus
10:00 a.m.–10:15 a.m.	Armored CAR T cells genetically modified to secrete IL-12 show enhanced efficacy and overcome a hostile tumor microenvironment in mouse ovarian peritoneal carcinomatosis* Oladapo Yeku, Memorial Sloan Kettering Cancer Center, New York, NY
10:15 a.m.–10:30 a.m.	A novel chimeric antigen receptor containing JAK-STAT signaling domains mediates superior antitumor effects* Yuki Kagoya, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
10:30 a.m.–11:00 a.m.	**Break** Salons EF Foyer
11:00 a.m.–12:45 p.m.	**Session 5: Structural Biology and Biomolecular Engineering of Immune Responses to Cancer** Salons EF
	Session Chairperson: Darrell J. Irvine, Koch Institute for Integrative Cancer Research, Cambridge, MA
11:00 a.m.–11:30 a.m.	Title to be announced Wendell Lim, University of California, San Francisco, CA
11:30 a.m.–12:00 p.m.	Engineering combination immunotherapy agents for synergistic innate and adaptive immune attack on solid tumors Darrell J. Irvine
12:00 p.m.–12:30 p.m.	Synergistic innate and adaptive immunotherapy K. Dane Wittrup, Massachusetts Institute of Technology, Cambridge, MA
12:30 p.m.–12:45 p.m.	Enhancing the efficacy of T cell-based immunotherapies using miR-155 engineered tumor-specific CD8+ T cells* Yun Ji, National Cancer Institute, Bethesda, MD

*Short talk from proffered abstract

CONFERENCE PROGRAM

12:45 p.m.–2:15 p.m. **Lunch on own/Free time**

2:15 p.m.–4:00 p.m. **Session 6: Single-Cell Immune Analyses**
Salons EF

Session Chairperson: Aviv Regev, Massachusetts Institute of Technology, Cambridge, MA

2:15 p.m.–2:45 p.m. Technologies for personalizing immunotherapies
James R. Heath, California Institute of Technology, Pasadena, CA

2:45 p.m.–3:15 p.m. Title to be announced
Garry P. Nolan, Stanford University School of Medicine, Stanford, CA

3:15 p.m.–3:45 p.m. Title to be announced
Aviv Regev

3:45 p.m.–4:00 p.m. Dissecting mechanisms of PD-1 blockade with single-cell RNA-sequencing*
Brian C. Miller, Dana Farber Cancer Institute, Boston, MA

4:00 p.m.–4:15 p.m. **Break**
Salons EF Foyer

4:15 p.m.–6:00 p.m. **Session 7: Imaging and Cancer Immunology**
Salons EF

Session Chairperson: Anna M. Wu, David Geffen School of Medicine at UCLA, Los Angeles, CA

4:15 p.m.–4:45 p.m. PET imaging of the immune system using new nucleoside analog probes
Caius G. Radu, University of California, Los Angeles, CA

4:45 p.m.–5:15 p.m. Profiling immune cell subsets and immune responses in vivo using immunoPET
Anna M. Wu

5:15 p.m.–5:45 p.m. Single domain antibody fragments as a platform for imaging and therapy
Hidde L. Ploegh, MIT Whitehead Institute for Biomedical Research, Cambridge, MA

5:45 p.m.–6:00 p.m. PET imaging of the PD-1/PD-L1 checkpoint in naive and radioimmunotherapy-treated tumor-bearing mice*
Gabriele Niedermann, University Clinics Freiburg, Freiburg, Germany

6:00 p.m.–8:45 p.m. **Poster Session B and Reception**
Back Bay

*Short talk from proffered abstract

SUNDAY, OCTOBER 23

7:30 a.m.–8:30 a.m.	**Breakfast** Back Bay
8:30 a.m.–9:30 a.m.	**Keynote Address** Salons EF
8:30 a.m.-9:30 a.m.	Personalizing cancer immunotherapy Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO
9:30 a.m.–10:00 a.m.	**Break** Salons EF Foyer
10:00 a.m.–12:15 p.m.	**Session 8: Genomics in Immuno-Oncology** Salons EF
	Session Chairperson: Nir Hacohen, The Broad Institute, Massachusetts General Hospital, Charlestown, MA
10:00 a.m.-10:30 a.m.	T cell recognition and tumor resistance in human cancer Ton Schumacher, Netherlands Cancer Institute, Amsterdam, The Netherlands
10:30 a.m.-11:00 a.m.	Drivers and resistors of tumor immunity Nir Hacohen
11:00 a.m.-11:30 a.m.	Genomic correlates of response and resistance to immune checkpoint blockade Eliezer M. Van Allen, Harvard Medical School, Boston, MA
11:30 a.m.-12:00 p.m.	T-cell transfer therapy targeting somatic mutations in human gastrointestinal cancers Eric Tran, National Cancer Institute, National Institutes of Health, Bethesda, MD
12:00 p.m.-12:15 p.m.	Inactivation of DNA repair triggers dynamic neoantigen evolution and impairs cancer growth* Giovanni Germano, Candiolo Cancer Institute, Candiolo, Italy
12:15 p.m.	**Closing Remarks and Departure** Salons EF

*Short talk from proffered abstract